Volume 5, Issue 3

PrEP for PWID?

Editor's note:

Technical difficulties unavoidably delayed the launch of this eHIV Review newsletter issue.  We apologize for any inconvenience this delay may have caused.

In this issue:

People who inject drugs (PWID) account for nearly 10% of new HIV infections. With the rate of injection drug use continuing to rise, the need for effective interventions to break the injection/infection cycle has become increasingly important. How effective is PrEP among PWID? What barriers prevent this population from receiving the HIV prevention services they need?

In this eHIV Review Issue, Dr. Jessica Taylor from the Boston University School of Medicine and Boston Medical Center analyzes the recent literature that investigates these critical questions.

Learning objectives:

  • Describe the evidence supporting HIV pre-exposure prophylaxis (PrEP) in people who inject drugs.
  • Discuss barriers to PrEP uptake in PWID and strategies to improve access.



Jessica Taylor, MD
Jessica Taylor, MD

Assistant Professor, General Internal Medicine

Boston University School of Medicine

Boston, MA

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 2, 2020
Expiration date: March 1, 2022